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Edited by Varda RotterAbstract The phytochemical 11,11 0-dideoxyverticillin, derived
from the fungus Shiraia bambusicola, has been shown to possess
potent anticancer activity in vitro and in vivo. Here, we investi-
gated the eﬀect of 11,11 0-dideoxyverticillin on cell cycle progres-
sion, and explored the potential mechanisms for this eﬀect. A
concentration- and time-dependent cell cycle blockade at G2/M
phase was observed in human colon cancer cells (HCT-116) fol-
lowing 11,11 0-dideoxyverticillin treatment and was associated
with marked increases in levels of p53, phospho-p53(ser20) and
phospho-Chk2(Thr 68). When wild type p53 expression was spe-
ciﬁcally inhibited by RNA interference, HCT-116 cells treated
with 11,11 0-dideoxyverticillin failed to arrest in G2/M and did
not show increased phospho-Chk2(Thr 68). On the other hand,
11,11 0-dideoxyverticillin treatment also elicited p38 MAP kinase
activity and expression of phospho-p38 MAPK. Treatment with
a speciﬁc p38 MAPK inhibitor (SB203580) successfully inhibited
p38 MAPK and delayed the onset of G2/M arrest induced by
0.5 lM 11,11 0-dideoxyverticillin after approximately 6 h, but
did not abolish the induction of G2/M arrest. Additionally,
SB203580 did not alter the levels of p53, phospho-p53 (ser20),
or phospho-Chk2 (Thr68) proteins in 11,11 0-dideoxyverticillin-
treated cells. Together, these ﬁndings indicate that p53-mediated
phosphorylation of Chk2 maybe plays a vital role in 11,11 0-dide-
oxyverticillin-induced G2/M arrest, and that p38 MAPK might
accelerate this progression. Our work suggests a new possibility
of interactions among p53, Chk2 and p38 MAPK signaling in
G2/M arrest.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Numerous anticancer drugs kill tumor cells by disrupting the
cell cycle. Activation of checkpoints in the G1 and G2 phasesAbbreviations: Chk1, checkpoint kinase 1; Chk2, checkpoint kinase 2;
p38 MAPK, p38 mitogen-activated protein kinase; DMSO, dimethyl
sulfoxide; FBS, fetal bovine serum; PBS, phosphate buﬀered saline; PI,
propidium iodide
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doi:10.1016/j.febslet.2005.05.053leads to cell cycle arrest, which provides time for repair of
damaged DNA or (in case of severe damage) activation of pro-
grammed cell death [1–3]. The G2 checkpoint is intricately reg-
ulated by a myriad of protein factors. Among them, p53,
checkpoint kinase 1 (Chk1), checkpoint kinase 2 (Chk2) and
p38 mitogen-activated protein kinase (p38 MAPK) have been
the most extensively investigated [4]. Continued research into
cell cycle regulation in general and these factors in speciﬁc will
allow us to better understand anticancer activities, and may
lead to the identiﬁcation of novel anticancer molecules.
The Chinese folk medicine fungus, Shiraia bambusicola,
grows on bamboo found primarily in several provinces in the
southern China. This fungus contains 11,11 0-dideoxyverticillin,
a potent small molecule compound (Fig. 1) capable of potently
inhibiting tyrosine kinase activity, especially that of epidermal
growth factor receptor (EGFR), in both molecular and cellular
models. The compound also exhibits cytotoxicity against a
broad spectrum of cancer cell lines in vitro, and has been
shown to suppress angiogenesis and reduce secretion of VEGF
from tumor cells [5,6].
Here, we further conﬁrmed the G2/M arrest elicited by
11,11 0-dideoxyverticillin in HCT-116 cells, examined its eﬀect
on wild type p53 and Chk2, deﬁned the role of p38 MAPK,
and investigated the possible relationships among these signals.2. Materials and methods
2.1. Agents
11,11 0-dideoxyverticillin was prepared from Shiraia bambusicola
Henn. The fungus was powdered and reﬂuxed three times with petro-
leum ether for 1 h each time. The defatted residue was then reﬂuxed
twice with 95% ethanol for 2 h each time. The combined ethanol ex-
tract was evaporated in vacuo; the aqueous residue was chloroform ex-
tracted three more times, and then subjected to column
chromatography over silica gel with a petroleum ether-acetone gradi-
ent (4:1ﬁ 1:1) as an eluent, to yield white 11,11 0-dideoxyverticillin
crystals (P 98% pure). The crystals were dissolved in dimethyl sulfox-
ide (DMSO), with the ﬁnal concentration of DMSO remaining below
0.1% (v/v) in all 11,11 0-dideoxyverticillin treated groups. DMSO 0.1%
(v/v) was used as a vehicle control throughout the study.
The p38 MAPK inhibitor, SB203580 (Calbiochem, Darmstadt, Ger-
many), was dissolved in DMSO at a concentration of 50 mM, and
stored at 20 C in the dark.
2.2. Cell culture
HCT-116 cells were obtained from the American Type Culture Col-
lection (Rockville, MD, USA) and cultured in McCoys 5A medium
(Gibco, Grand Island, NY, USA) with 10% heat-inactivated fetalblished by Elsevier B.V. All rights reserved.
Fig. 1. Chemical structure of 11,11 0-dideoxyverticillin.
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streptomycin. Cells were incubated under standard cell culture condi-
tions at 37 C and 5% CO2 in a humid environment.
2.3. p53 siRNA transfection
Cells (0.8 · 105) were incubated overnight in 24-well dishes in
McCoys 5A medium containing 10% FBS. On day 2, the medium
was replaced with fresh medium containing 50 nM p53 siRNA (Cell
Signaling Technology, Beverly, MA, USA; 5 0-CUACUUCCU-
GAAAACAACGTT) and Oligofectamine (Invitrogen, Carlsbad,
CA, USA) according to the manufacturers recommendations. Forty-
eight hours after transfection, cell lysates were prepared for Western
blot analysis for detection of p53 expression and cell cycle analysis.
2.4. Cell cycle analysis
The distribution of cells at diﬀerent stages in the cell cycle was esti-
mated by ﬂow cytometric DNA analysis as described previously [7].
Brieﬂy, 5 · 105 cells were incubated overnight in 6-well dishes in med-
ium containing 10% FBS, then for diﬀerent times with or without var-
ious concentrations of 11,11 0-dideoxyverticillin, or with SB203580
pretreatment for 30 min, in HCT-116 cells or in transfected cells. Cells
were harvested, washed twice with cold phosphate buﬀered saline
(PBS, pH 7.4), and ﬁxed with 70% ethanol/30% PBS at 4 C. The ﬁxed
cells were incubated with 0.5 ml PBS containing 10 lg/ml RNase for
30 min at 37 C, then stained with 20 lg/ml propidium iodide (PI,
Sigma, St. Louis, MO, USA) for 30 min in the dark at room temper-
ature, and ﬁnally analyzed on a FACS cytometer (Calibur, Becton
Dickinson, USA). A minimum of 1 · 104 cells/sample was evaluated,
and the percentage of cells in each cell cycle phase was calculated
using the CELLQUEST and ModFITLT software packages (Becton
Dickinson).
2.5. Western blot analysis
Cell lysates were prepared in lysis buﬀer (2 mM sodium orthovan-
adate, 50 mM NaF, 20 mM HEPES, 150 mM NaCl, 1.5 mM MgCl2,
5 mM sodium pyrophosphate, 10% glycerol, 0.2% Triton X-100,
5 mM EDTA, 1 mM PMSF, 10 lg/ml leupeptin and 10 lg/ml aproti-
nin) on ice for 30 min. Samples were clariﬁed by centrifugation at
4 C for 15 min at 13 000 · g, and then equal amounts of protein
were separated on SDS–polyacrylamide gels under reducing condi-
tions and transferred to nitrocellulose membranes. The blots were
incubated overnight at 4 C with the following antibodies: anti-p53
antibody, anti-phospho-p53(ser20) antibody, anti-p38MAPK anti-
body, anti-phospho-p38 MAPK antibody, anti-Chk1 antibody,
anti-phospho-Chk1(Ser 345) antibody, anti-Chk2 antibody and
anti-phospho-Chk2(Thr 68) antibody (all diluted 1:1000 and obtained
from Cell Signaling Technology, Beverly, MA, USA). Bands were
visualized using horseradish peroxidase-conjugated secondary anti-
bodies (Calbiochem, Darmstadt, Germany, diluted 1:2000) followed
by enhanced chemiluminescence detection (ECL, Pierce Biotech,
Rockford, IL, USA).2.6. p38 MAP kinase assay
The p38 MAP kinase assay was carried out using the appropriate kit
(Cell Signaling Technology) according to the manufacturers instruc-
tions. In brief, 1 · 107 cells were incubated overnight in 6-well dishes
in medium containing 10% FBS, then treated for diﬀerent times with
or without various concentrations of 11,11 0-dideoxyverticillin, with or
without pretreatment with SB203580 for 30 min. Cells were washedwith
ice-cold PBS and lysed in 500 ll of lysis buﬀer (20 mM Tris pH 7.5,
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM so-
dium pyrophosphate, 1 mM Na3VO4, 1 mM b-glycerophosphate,
1 mg/ml leupeptin, and 1 mM PMSF). The lysates were sonicated and
centrifuged. The resulting supernatants (containing 200 lg total pro-
tein) were incubated with an immobilized phospho-p38 MAPK anti-
body (Thr180/Tyr182) with gentle shaking overnight at 4 C. The
beads were washed twice with 500 ll of lysis buﬀer and twice with
500 ll of kinase buﬀer (25 mM Tris pH 7.5, 5 mM b-glycerophosphate,
2 mMDTT, 0.1 mMNa3VO4, and 10 mMMgCl2), and kinase reactions
were carried out in the presence of 200 lMATP, and 2 lg of ATF-2 at
30 C for 30 min. Phosphorylation of ATF-2 at Thr71 was selectively
measured by Western blotting (Cell Signaling Technology) using a
chemiluminescent detection system (Cell Signaling Technology).3. Results
3.1. Treatment with 11,11 0-dideoxyverticillin arrests HCT-116
cells in G2/M phase
The eﬀect of 11,11 0-dideoxyverticillin treatment on cell cycle
progression of HCT-116 cells was examined at varying doses
and time points by ﬂow cytometry. Treatment with 11,11 0-
dideoxyverticillin resulted in a concentration- and time-
dependent increase in the G2/M phase cell population and a
corresponding decrease in the G1 and S phase populations
(Fig. 2). Treatment with 0.12 lM 11,11 0-dideoxyverticillin for
6 h increased the percentage of cells in the G2/M phase from
15.90% (control) to 16.44%, and treatment of the same dura-
tion with 1.0 lM 11,11 0-dideoxyverticillin further increased
the G2/M population to 27.48% (Fig. 2(b)). Treatment with
0.5 lM 11,11 0-dideoxyverticillin increased the G2/M popula-
tion within as little as 1 h, and this population continued to in-
crease with time; at 6 h, the percentage of the cells at G2/M
phase was 30.33% and at 10 h it was 37.99%, signiﬁcantly
diﬀerent from that of the control (18.73%) (Fig. 2(a)).
3.2. Treatment with 11,11 0-dideoxyverticillin enhances levels of
p53 and phosphorylated p53 (Ser20)
Treatment with 11,11 0-dideoxyverticillin may elicit G2/M
arrest via triggering G2/M checkpoint protein, such as p53
[8–10]. Although the signiﬁcance of individual residues to
p53 activation is not entirely clear, phosphorylation of the
serine residue at position 20 appears to be essential to p53
stabilization [11,12]. Accordingly, we investigated whether
11,11 0-dideoxyverticillin aﬀected the expression of p53 and
phospho-p53(ser20) proteins in HCT-116 cells. Treatment with
11,11 0-dideoxyverticillin for 4 h increased the levels of p53 and
phospho-p53(ser20) in a dose-dependent fashion (Fig. 3(a)).
The same trend was observed when cells were exposed to
0.5 lM 11,11 0-dideoxyverticillin for increasing durations
(Fig. 3(b)). Notably, the increase in phospho-p53(ser20)
seemed to lag slightly behind that of p53, though the levels
of both p53 and phospho-p53(ser20) rose time- and dose-
dependently (Fig. 3). These data suggest that 11,11 0-dideoxy-
verticillin can promote p53 expression and/or stabilization,
and indicate that p53 signaling may participate in 11,11 0-dide-
oxyverticillin-triggered G2/M arrest.
Fig. 2. Eﬀect of 11,110-dideoxyverticillin on cell cycle distribution in HCT-116 cells. Cells were collected, and processed for cytometric analysis of cell
cycle distribution. The data are expressed as X  S.D. from three independent experiments. (a) Cells were treated with 0.5 lM for diﬀerent time
points; (b) HCT-116 cells were treated with various doses of 11,11 0-dideoxyverticillin for 6 h. The signiﬁcance was assessed with a students t-test.
\P < 0.05 compared with control, \\P < 0.01 compared with control.
Y. Chen et al. / FEBS Letters 579 (2005) 3683–3690 36853.3. p53 siRNA abrogates the 11,11 0-dideoxyverticillin-elicited
G2/M arrest
To further deﬁne the role of p53 signaling in 11,11 0-dideoxy-
verticillin-induced cell cycle arrest, we used RNA interference
to speciﬁcally inhibit p53 expression in HCT116 cells. The
interfering RNA molecules silenced p53 expression (Fig. 4),
and abolished 11,11 0-dideoxyverticillin-elicited G2/M arrest
(Fig. 5). In striking contrast to cells treated with 0.5 lM
11,11 0-dideoxyverticillin alone (Fig. 2(a)), those transfected
with p53 siRNA showed relatively stable G2/M populations
even up to 10 h; at this time, the percentage of the cells at
G2/M phase was 25.54% in the experimental group, which
was not signiﬁcantly diﬀerent from the control (23.70%).
And treatment of control siRNA transfected cells with
11,11 0-dideoxyverticillin 0.5 lM for 10 h still resulted in in-
crease in G2/M phase cells. Correspondingly, 11,11
0-dideoxy-verticillin did not enhance p53 expression in the p53 siRNA-
transfected cells (Fig. 4). Together, these results indicate that
p53 signaling is integral to G2/M arrest in 11,11
0-dideoxyvert-
icillin-treated HCT-116 cells.
3.4. 11,11 0-dideoxyverticillin treatment stimulates
phosphorylation of Chk2 (Thr68), and this stimulation is
abrogated by p53 siRNA
Chk1 and Chk2, two other factors associated with G2/M ar-
rest, can be activated by phosphorylation of Ser345 and Thr68,
respectively [13,14]. Accordingly, we examined whether activa-
tion of these proteins was aﬀected by 11,11 0-dideoxyverticillin.
Treatment with the agent increased phospho-Chk2 (Thr 68)
protein levels in a concentration- and time-dependent fashion;
this increase lagged slightly behind the observed increases in
p53 and phospho-p53(ser20) (Fig. 3). In contrast, treatment
Fig. 3. 11,11 0-dideoxyverticillin aﬀects the levels of G2/M related
regulators in HCT-116 cells, as determined by Western blotting
analysis. Cells were treated as indicated and lysates were electropho-
resed on 10% SDS–polyacrylamide gels. (a) Concentration-dependent
eﬀect. The cells were treated for 4 h prior to detection of p53 and p-p53
(ser20); Chk1, p-Chk1 (Ser345), Chk2 and p-Chk2 (Thr68) were
detected after cells had been treated for 8 h. (b) Time-dependent eﬀect.
Experiments were repeated three times.
Fig. 4. Eﬀect of siRNA-based p53 protein depletion on 11,11 0-
dideoxyverticillin-induced phosphorylation of Chk2 (Thr68) and p38.
p53 siRNA-transfected HCT-116 cells were treated with 0.5 lM
11,11 0-dideoxyverticillin for the indicated times, harvested, and pro-
cessed for immunoblotting.
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levels and/or phosphorylation at any examined concentration
or time point. We then used the p53 siRNA to tested the
involvement of p53 in the 11,11 0-dideoxyverticillin-induced
upregulation of Chk2 phosphorylation. Cells transfected with
the p53 siRNA showed no change in phospho-Chk2 (Thr 68)
levels following treatment with 0.5 lM 11,11 0-dideoxyverticil-
lin for up to 10 h (Fig. 4). Together, these data indicate that
Chk2, but not Chk1, may be involved in G2/M arrest and
p53 signaling in 11,11 0-dideoxyverticillin-treated HCT-116
cells.
3.5. 11,11 0-dideoxyverticillin activates p38 MAPK
Next, we examined whether p38 MAPK is involved in medi-
ating 11,11 0-dideoxyverticillin-induced G2/M arrest. We found
that treatment of cells with 11,11 0-dideoxyverticillin increased
phospho-p38 MAPK levels in a dose-dependent fashion, but
that the total amount of p38 MAPK stayed unchanged (Fig.
6(a)). After treatment with 0.5 lM 11,11 0-dideoxyverticillin,
the level of phospho-p38 MAPK was expressed highest at6 h, then it slight down a little but still at a high level. We fur-
ther measured the kinase activity of p38 MAPK in an immu-
nocomplex kinase assay in which p38 MAPK was speciﬁcally
immunoprecipitated from 11,11 0-dideoxyverticillin-treated
cells and used to phosphorylate a test substrate, ATF2. The re-
sults showed that p38 MAP kinase activity was signiﬁcantly
higher in 11,11 0-dideoxyverticillin-treated cells as compared
to control cells. ATF-2 phosphorylation began to increase
15 min after the addition of 11,11 0-dideoxyverticillin, and re-
mained elevated for 6 h. The kinase activity also rose in a
dose-dependent manner (Fig. 6(b)). Interestingly, addition of
p53 siRNA did not abrogated the 11,11 0-dideoxyverticillin-
induced increase of phospho-p38 MAPK levels (Fig. 4). To-
gether, these data suggest that p38 MAPK may contribute to
11,11 0-dideoxyverticillin-induced G2/M arrest, but that p38
MAPK is not strictly downstream of the p53 signaling cascade
in this context.
3.6. A speciﬁc p38 MAPK inhibitor delays but does not abolish
11.11 0-dideoxyverticillin-induced G2/M arrest
SB203580, a p38 MAPK-speciﬁc inhibitor, was used to
determine the contribution of p38 MAPK signaling in
11,11 0-dideoxyverticillin-induced cell cycle arrest. Pretreatment
with 20 lM SB203580 for 30 min removed the 11,11 0-dideoxy-
verticillin-inducible ability of p38 MAPK to phosphorylate its
substrate, ATF2 (Fig. 6). Correspondingly, inhibitor pretreat-
ment signiﬁcantly delayed the initiation of the G2/M arrest
elicited by 11,11 0-dideoxyverticillin (Fig. 7), with arrest occur-
Fig. 5. p53 siRNA reverses 11,11 0-dideoxyverticillin-induced G2/M arrest in HCT-116 cells. Cells were transfected with 50 nM p53 siRNA, and
exposed to 0.5 lM 11,11 0-dideoxyverticillin for the indicated times, then the cell cycle distributions were detected. The data are expressed as
means ± S.D. from three independent experiments. The signiﬁcance was assessed with a students t-test. \P < 0.05 compared with control.
Fig. 6. 11,11 0-dideoxyverticillin activates p38 MAP kinase in HCT-116 cells. Cells were treated with various doses of 11,110-dideoxyverticillin for 4 h,
or 0.5 lM 11,11 0-dideoxyverticillin for the indicated times. (a) Cells lysates were immunoblotted and p38 and p-p38 MAPK levels were detected. (b)
Total cell lysates were immunoprecipitated with anti-p38 MAPK antibody, and p38 MAP kinase activity was assayed using GST-ATF-2 as a
substrate.
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pretreated cells (Fig. 2(a)). However, inhibitor pretreatment
did not abrogate G2/M arrest; the percentage of the cells at
G2/M phase was 28.25% at 8 h after 11,11
0-dideoxyverticillin
treatment, and 30.82% at the 10 h post-treatment, diﬀerent
form the control (18.06%). Additionally, we found that pre-treatment with 20 lM SB203580 for 30 min had no impact
on the 11,11 0-dideoxyverticillin-induced enhancement of p53,
phospho-p53(ser20), and phospho-Chk2(Thr 68) protein levels
(Fig. 8). Together, these data indicate that p38 MAPK signal-
ing can accelerate 11,11 0-dideoxyverticillin-induced G2/M ar-
rest, but does not determine its occurrence.
Fig. 7. SB203580 (a p38 MAPK-speciﬁc inhibitor) delays 11,110-dideoxyverticillin-induced G2/M arrest in HCT-116 cells. Cells were pretreated for
30 min with 20 lM SB203580 before being exposed to 0.5 lM 11,110-dideoxyverticillin for the indicated times, after which cell cycle distributions
were detected. The data are expressed as means ± S.D. from three independent experiments. The signiﬁcance was assessed with a students
t-test. \P < 0.05 compared with SB203580 (20 lM, 0 h), \\P < 0.01 compared with SB203580 (20 lM, 0 h), # P < 0.05 compared with SB203580
(0 lM, 0 h).
Fig. 8. SB203580 has no eﬀect on 11,110-dideoxyverticillin-induced phosphorylation of p53(Ser20) and Chk2(Thr68) in HCT-116 cells. Cells were
pretreated for 30 min with 20 lM SB203580 and then treated with the indicated conditions of 11,11 0-dideoxyverticillin for the indicated times before
being harvested, and processed for immunoblotting. (a) Concentration-dependent eﬀect. The cells were treated for 4 h and p53 and p-p53 (ser20) were
detected. p-Chk2 (Thr68) was detected after cells had been treated for 8 h. (b) Time-dependent eﬀect.
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Cell cycle regulation is a complicated process involving
many signaling molecules interacting in ways that are not yet
fully understood. This study clariﬁes the relationships among
p53, Chk2, and p38 MAPK on the basis of evaluating their
roles in 11,11 0-dideoxyverticillin-elicited G2/M arrest.
11,11 0-dideoxyverticillin displays potent anti-tumor activity
in a variety of human cancer cell lines and anti-angiogenetic ef-fect against numerous in vitro and ex vivo models. This study
further revealed that the compound could arrest HCT-116 cells
in G2/M phase in a dose- and time-dependent manner, in a
process associated with increases in p53, phospho-p53 (ser20)
and phospho-Chk2 (Thr68) protein levels. Silencing of p53
with p53 siRNA abrogated the enhancement of p53 and phos-
pho-p53 (ser20) proteins, and protected HCT-116 cells against
11,11 0-dideoxyverticillin-induced G2/M arrest, indicating that
p53 signaling plays an important role in 11,11 0-dideoxyverticil-
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Chk2 was increased by 11,11 0-dideoxyverticillin treatment,
and this increase was eliminated by application of p53 siRNA.
In contrast, p38 MAP kinase activity was increased by 11,11 0-
dideoxyverticillin treatment, but this increase was not altered
by pre-treatment with the p53 siRNA. SB203580, a p38
MAPK-speciﬁc inhibitor, delayed but did not abolish 11,11 0-
dideoxyverticillin-induced G2/M arrest, and had no eﬀect on
the p53, phospho-p53(ser20), or phospho-Chk2(Thr 68) pro-
tein levels in 11,11 0-dideoxyverticillin-treated cells. These re-
sults clearly show close interactions among p53, Chk2, and
p38 MAPK signals in 11,11 0-dideoxyverticillin-induced G2/M
arrest.
Both p53 and Chk2 are well known as checkpoint regulators
[15] and have been shown to participate in 11,11 0-dideoxyvert-
icillin-induced G2/M arrest. However, their precise pathway
order was not previously known. Some previous studies impli-
cated Chk2 in the phosphorylation and stabilization of p53
proteins [11,16–19]. For example, Chk2/ mouse embryonic
stem cells were defective for p53 stabilization, failed to express
p53-dependent transcripts such as p21 in response to IR, and
were unable to maintain IR-induced G2 arrest. Reintroduction
of the Chk2 gene restored p53-dependent transcription in re-
sponse to c irradiation. Moreover, Chk2 was found to directly
phosphorylate GST-p53 on Ser20 [18]. Similarly, speciﬁc inhi-
bition of Chk2 activity with UCN-01 prevented Chk2-medi-
ated p53 phosphorylation at serine 20 in IR-treated HCT116
cells [19]. Recently, Jallepalli et al. [20] disrupted the Chk2
gene through homologous recombination and examined
whether Chk2 kinase acted as the primary mediator of p53
phosphorylation. Unexpectedly, they found that Chk2 was
not required for p53 stability and response. Furthermore,
Chk2 puriﬁed from DNA damage-sustaining cells only weakly
phosphorylated p53, and there was no increase in its activity
toward p53 after DNA damage by c irradiation or the radio-
mimetic agent neocarzinostatin [21]. And ﬁnally, introduction
of Chk2 short interfering RNA or vectors into HCT116 cells
inhibited Chk2 protein expression, but p53 was still stabilized
and active after DNA damage [21]. These lines of evidence
indicate that Chk2 does not control p53. In contrast, a more
recent study suggested that p53 regulates Chk2 expression in
a tissue-speciﬁc manner [22]. This work showed that elevated
mChk2 and Chk2 protein expression was detected in the heart,
kidney, liver, and lungs of p53+/+ mice as compared to p53/
 mice. In addition, our current study showed that 11,11 0-
dideoxyverticillin increased p53, phospho-p53(ser20), and
phospho-Chk2(Thr 68) proteins levels, with p53 and phos-
pho-p53(ser20) increasing prior to phospho-Chk2(Thr 68).
More importantly, transfection of cells with p53 siRNA trans-
fection abrogated the 11,11 0-dideoxyverticillin-induced
enhancement of phospho-Chk2(Thr 68) protein levels. These
data clearly show that p53 can regulate the phosphorylation
of Chk2(Thr 68), and the p53 siRNA transfection results fur-
ther indicate that the p53 pathway plays a central role in
11,11 0-dideoxyverticillin-triggered G2/M arrest.
p38 MAPK has traditionally been considered part of the
stress and immune responses, but several recent reports have
indicated that it also plays an important role in regulation of
cell cycle progression. p38 MAPK is involved in G2 arrest trig-
gered by UV and ionizing irradiation [23,24], and inhibition of
p38 MAPK (by inhibitor treatment or protein depletion using
antisense oligonucleotides) blocked the rapid initiation of thischeckpoint in both human and murine cells after ultraviolet
radiation [23]. Moreover, when cells are treated with UV or
certain anticancer drugs, p38 MAPK can activate p53 by phos-
phorylating multiple sites, including serines 33, 46, and 389
[25–27]. Chk2 was previously shown to be activated in an
MKK6-p38c-dependent manner in response to c-radiation-
induced G2 arrest [24]. Otherwise, Manke et al. [28] proposed
recently that p38 MAPK activated its directly downstream tar-
get MAPKAP kinase-2, which is responsible for phosphorylat-
ing Cdc25B and C and maintaining the G1, S, and G2/M
checkpoints in response to UV-induced DNA damage. They
think that MAPKAP kinase-2 constitutes a third checkpoint
kinase, in addition to Chk1 and Chk2, involved in coordinat-
ing the DNA damage response and regulating G2/M transition
and S phase progression in mammalian cells. Here, we further
validated the rapid initiation of p38 MAPK in 11,11 0-dideoxy-
verticillin-elicited G2/M arrest, and showed that a p38 MAPK-
speciﬁc inhibitor (SB203580) delayed the onset of G2/M arrest
up to approximately 6 h (as compared to 1 h in cells not trea-
ted with the inhibitor), but did not abrogate the 11,11 0-dide-
oxyverticillin-induced arrest. Furthermore, inhibition of p38
MAPK did not change the levels of 11,11 0-dideoxyverticillin-
induced active p53 and Chk2 proteins. Hence, the p38 MAPK
signaling maybe merge into the downstream of the p53 path-
way and synergize this pathway. In our case, p38 MAPK sig-
naling seems to determine when the arrest begins, whereas the
signaling from the p53 pathway determines whether it takes
place or not.
In summary, we have demonstrated that a novel signaling
relationship may exist among p53, Chk2, and p38 MAPK.
The p53ﬁ Chk2 pathway transduces the critical signal trig-
gered by 11,11 0-dideoxyverticillin, which leads to the G2/M ar-
rest. Activation of p38 signaling by the agent accelerates this
progression, though p38 MAPK does not serve as a member
of this pathway. These results provide new insights into the
complicated process of cell cycle regulation and allow us to
further understand the molecular mechanisms by which
11,11 0-dideoxyverticillin exerts its anticancer activities. Never-
theless, some molecular links remain to be clariﬁed, such as
how the p53 signaling is connected to Chk2, and how p38 sig-
naling acts on the p53 pathway.
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